Real-Life Use of Tixagevimab-Cilgavimab for the Treatment of Early Covid-19

UOC Emerging Infectious Disease with High Contagiousness, AORN Ospedali dei Colli P.O. C Cotugno, 80131 Naples, Italy.
Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Napoli, Italy
Department of Experimental Medicine - Section of Pharmacology �??L. Donatelli�?�, University of Campania �??Luigi Vanvitelli�?�, Napoli, Italy
UOSD Pharmacovigilance AORN Ospedali dei Colli P.O. C Cotugno, 80131 Naples, Italy.

Scientific Tracks Abstracts: Health Sci J

Abstract:

Background Tixagevimab-cilgavimab are effective for treatment of early COVID-19 among outpatients with risk factors for progression to severe illness, as well as for primary prevention and post-exposure prophylaxis. We aimed to retrospectively evaluate the Hospital stay, prognosis and COVID19 related inflammation in patients with immune system deficiency underwent Tixagevimab– cilgavimab. Materials and Methods In this observational retrospective study we enrolled 42 patients who were nasal swab positive for SARS-COV-2 (Antigenic and molecular) and hospitalized at the first division of the Cotugno Hospital in Naples from 8 july 2022 to 10 january 2023. We randomly selected from our database patients matched for age, sex and disease: Group A (27 patients) affected from chronic degenerative disorders and Group B (15 patients) affected oncohaematological diseases (LNH, LLC). Results According to our data we observed that mean stay of patients in group A was (21±5 days) vs (25±5 days) Group B without any statistical significance differences Sign Test (p <0.05); exitus were 4 in both groups; no differences in IL-6 levels between studied groups; we found differences only in PCR at admission being higher in group A compered group B. Patients enrolled in group A came to our observation after 10 days from the detection of positivity to COVID-19 unlike the other types of patients enrolled in this study. The mean stay in hospital of patients in Group A was 21±5 days vs 25±5 days in Group B. Twenty patients resulted negative after a median of hospitalization stay of 16 days (IQR: 18-15.25), of them 5 (25%) patients belonged to group B. We observed that patients with Lymphoprolipherative disorders had lower PCR levels compared to those with chronic degenerative disorders; however both groups despite the use with active of tixagevimab-cilgavimab in association with Remdesivir does not have any significant benefit in terms of days of infection or prognosis. Conclusion Patients with active hematological malignancy are those with the worst prognosis for COVID-19, despite the therapy with tixagevimab-cilgavimab and remdesivir. It could be useful to sensitize hematologists and patients with active hematological malignancies to early start the pharmacological treatment (within 10 days from the detection of COVID-19 positivity). Further studies with an adequate sample size are needed to better elucidate the efficacy and safety of tixagevimab-cilgavimab in patients with COVID-19 and affected by chronic comorbidities or an impaired immune response.

PDF HTML